Table 1 Comorbidities, complications, and management of patients with and without cough or sputum in PRO after 12 months

Clinical characteristics

 Age, mean (95%CI)

64 (55.75–73.75)

59 (47–71)

0.038^a

65 (53–75)

59 (47–70)

0.036^a

 Male, n (%)

24 (75)

422 (61)

0.111^b

30 (83.3)

416 (60.5)

0.006^b

 BMI, mean (95%CI)

24.33 (22.14–27.71)

23.77 (21.45–26.26)

0.290^a

23.77 (21.51–26.3)

24.14 (21.84–25.35)

0.917^a

Current smoking, n (%)

4 (12.5)

70 (10.1)

0.693^b

6 (16.7)

68 (10)

0.161^b

 Smoking history, n (%)

17 (53.1)

239 (34.5)

0.021^b

18 (50)

238 (34.6)

0.042^b

Comorbidities, n (%)

 Hypertension

19 (59.4)

238 (34.4)

0.004^b

19 (52.8)

238 (34.6)

0.028^b

 Diabetes

14 (43.8)

108 (15.6)

< 0.001^b

6 (16.7)

114 (16.6)

0.988^b

 Cardiovascular disease

3 (9.4)

40 (5.8)

0.409^b

2 (5.6)

41 (59.6)

0.911^b

 Malignancy

2 (6.3)

40 (5.8)

0.920^b

2 (5.6)

40 (58.1)

0.940^b

 COPD

2 (6.3)

22 (3.2)

0.350^b

3 (8.3)

21 (3.1)

0.088^b

 Asthma

4(12.5)

36 (5.2)

0.082^b

4 (11.1)

36 (5.2)

0.139^b

 Hyperuricemia

3 (9.4)

77 (11.1)

0.743^b

7 (19.4)

73 (10.6)

0.105^b

 Chronic liver disorder

1 (3.1)

26 (3.8)

0.841^b

1 (2.8)

26 (3.8)

0.745^b

 Chronic kidney disease

5 (15.6)

29 (4.2)

0.002^b

2 (5.6)

32 (4.7)

0.789^b

Management, n (%)

 ICU

7 (21.9)

65 (9.4)

0.024^b

6 (16.7)

66 (9.6)

0.183

 Mechanical ventilator

5 (15.6)

32 (4.6)

0.007^b

6 (16.7)

31 (4.5)

0.002^b

 Use of IMV/NPPV/NHF

5 (15.6)

42 (6.1)

0.036^b

6 (16.7)

41 (6.0)

0.013^b

Abbreviation: PRO, patient reported outcome; BMI, body mass index; COPD, chronic obstructive pulmonary disease. ICU, intensive care unit.